Boostrix Injection

Boostrix Injection is a combination vaccine formulated to provide active booster immunization against diphtheria, tetanus, and pertussis (whooping cough). It contains Diphtheria Toxoid 2IU, Filamentous Haemagglutinin 8mcg, Pertactin 2.5mcg, Pertussis Toxoid 8mcg, and Tetanus Toxoid 20IU per 0.5ml dose. This vaccine stimulates the immune system to develop protection against these infections, making it suitable for individuals from four years of age onwards requiring booster vaccination.

The vaccine is administered as a 0.5ml deep intramuscular injection, preferably into the deltoid region. A single 0.5ml dose is recommended, with repeat vaccination generally advised at intervals of 10 years, in accordance with official recommendations. Boostrix is also indicated for immunization during the third trimester of pregnancy to help prevent pertussis in infants younger than two months of age.

For optimal efficacy and stability, Boostrix Injection must be stored in a refrigerator between +2°C and +8°C. It is crucial not to freeze the vaccine, as freezing destroys its effectiveness, and any frozen product should be discarded. The vaccine should be stored in its original packaging to protect it from light. Boostrix is manufactured by GlaxoSmithKline Biologicals s.a. and holds regulatory approval from the FDA and is WHO Prequalified.

Key Features : 

Antigen composition includes Diphtheria Toxoid, Filamentous Haemagglutinin, Pertactin, Pertussis Toxoid, and Tetanus Toxoid.
Approved for active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older, and for immunization during the third trimester of pregnancy to prevent pertussis in infants younger than two months of age.
Requires cold-chain storage at temperatures between 2°C and 8°C; must not be frozen.
Administered via deep intramuscular injection, typically into the deltoid muscle.
Holds regulatory approval from the FDA and is WHO Prequalified.